|
1
|
Varma R, Lee PP, Goldberg I and Kotak S:
An assessment of the health and economic burdens of glaucoma. Am J
Ophthalmol. 152:515–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fishman P, Bar-Yehuda S and Madi L:
Adenosine, tumors and immunity. Adenosine Receptors: Therapeutic
Aspects for Inflammatory and Immune Diseases. Hasko G, Cronstein BN
and Szabo C: Taylor and Francis; London: pp. 299–312. 2007
|
|
3
|
Chen GJ, Harvey BK, Shen H, et al:
Activation of adenosine A3 receptors reduces ischemic
brain injury in rodents. J Neurosci Res. 84:1848–1855. 2006.
|
|
4
|
David M, Akerman L, Ziv M, et al:
Treatment of plaque-type psoriasis with oral CF101: data from an
exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol
Venereol. 26:361–367. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Avni I, Garzozi HJ, Barequet IS, et al:
Treatment of dry eye syndrome with orally administered CF101: data
from a phase 2 clinical trial. Ophthalmology. 117:1287–1293. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Silverman MH, Strand V, Markovits D, et
al: Clinical evidence for utilization of the A3
adenosine receptor as a target to treat rheumatoid arthritis: data
from a phase II clinical trial. J Rheumatol. 35:41–48.
2008.PubMed/NCBI
|
|
7
|
Bagnis A, Papadia M, Scotto R and Traverso
CE: Current and emerging medical therapies in the treatment of
glaucoma. Expert Opin Emerg Drugs. 16:293–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qu J, Wang D and Grosskreutz CL:
Mechanisms of retinal ganglion cell injury and defense in glaucoma.
Exp Eye Res. 91:48–53. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakazawa T, Nakazawa C, Matsubara A, et
al: Tumor necrosis factor-alpha mediates oligodendrocyte death and
delayed retinal ganglion cell loss in a mouse model of glaucoma. J
Neurosci. 26:12633–12641. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sivakumar V, Foulds WS, Luu CD, et al:
Retinal ganglion cell death is induced by microglia derived
pro-inflammatory cytokines in the hypoxic neonatal retina. J
Pathol. 224:245–260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baudouin C, Liang H, Hamard P, et al: The
ocular surface of glaucoma patients treated over the long term
expresses inflammatory markers related to both T-helper 1 and
T-helper 2 pathways. Ophthalmology. 115:109–115. 2008. View Article : Google Scholar
|
|
12
|
Leske MC, Wu SY, Hennis A, et al; BESs
Study Group. Risk factors for incident open-angle glaucoma: the
Barbados Eye Studies. Ophthalmology. 115:85–93. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
The European Glaucoma Society. Treatment
principles and options. Terminology and Guidelines for Glaucoma.
Heijl A and Traverso CE: 3rd edition. Dogma SRL; Savona: pp.
117–131. 2008
|
|
14
|
Reardon G, Kotak S and Schwartz GF:
Objective assessment of compliance and persistence among patients
treated for glaucoma and ocular hypertension: a systematic review.
Patient Prefer Adherence. 5:441–463. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Strahlman E, Tipping R and Vogel R: A
double-masked, randomized 1-year study comparing dorzolamide
(Trusopt), timolol and betaxolol. International Dorzolamide Study
Group. Arch Ophthalmol. 113:1009–1016. 1995.
|
|
16
|
Baudouin C, Hamard P, Liang H, et al:
Conjunctival epithelial cell expression of interleukins and
inflammatory markers in glaucoma patients treated over the long
term. Ophthalmology. 111:2186–2192. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pisella PJ, Debbasch C, Hamard P, et al:
Conjunctival proinflammatory and proapoptotic effects of
latanoprost and preserved and unpreserved timolol: an ex vivo and
in vitro study. Invest Ophthalmol Vis Sci. 45:1360–1368. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rusk C, Sharpe E, Laurence J, et al:
Comparison of the efficacy and safety of 2% dorzolamide and 0.5%
betaxolol in the treatment of elevated intraocular pressure.
Dorzolamide Comparison Study Group. Clin Ther. 20:454–466.
1998.
|
|
19
|
Katz LJ: Twelve-month evaluation of
brimonidine-purite versus brimonidine in patients with glaucoma or
ocular hypertension. J Glaucoma. 11:119–126. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feldman RM: Conjunctival hyperemia and the
use of topical prostaglandins in glaucoma and ocular hypertension.
J Ocul Pharmacol Ther. 19:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cohen S, Stemmer SM, Zozulya G, et al:
CF102 an A3 adenosine receptor agonist mediates
anti-tumor and anti-inflammatory effects in the liver. J Cell
Physiol. 226:2438–2447. 2011.PubMed/NCBI
|
|
22
|
Fishman P, Bar-Yehuda S, Barer F, et al:
The A3 adenosine receptor as a new target for cancer
therapy and chemoprotection. Exp Cell Res. 269:230–236. 2001.
|
|
23
|
Matot I, Weiniger CF, Zeira E, et al:
A3 adenosine receptors and mitogen-activated protein
kinases in lung injury following in vivo reperfusion. Crit Care.
10:R652006. View
Article : Google Scholar
|
|
24
|
Xu Z, Jang Y, Mueller RA and Norfleet EA:
IB-MECA and cardioprotection. Cardiovasc Drug Rev. 24:227–238.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ge ZD, Peart JN, Kreckler LM, et al:
Cl-IB-MECA
[2-chloro-N6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide]
reduces ischemia/reperfusion injury in mice by activating the
A3 adenosine receptor. J Pharmacol Exp Ther.
319:1200–1210. 2006.
|
|
26
|
Shneyvays V, Leshem D, Zinman T, et al:
Role of adenosine A1 and A3 receptors in
regulation of cardiomyocyte homeostasis after mitochondrial
respiratory chain injury. Am J Physiol Heart Circ Physiol.
288:H2792–H2801. 2005.PubMed/NCBI
|
|
27
|
Zhang M, Hu H, Zhang X, et al: The
A3 adenosine receptor attenuates the calcium rise
triggered by NMDA receptors in retinal ganglion cells. Neurochem
Int. 56:35–41. 2010.
|
|
28
|
Zhang X, Zhang M, Laties AM and Mitchell
CH: Balance of purines may determine life or death of retinal
ganglion cells as A3 adenosine receptors prevent loss
following P2X7 receptor stimulation. J Neurochem. 98:566–575. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schlötzer-Schrehardt U, Zenkel M, Decking
U, et al: Selective upregulation of the A3 adenosine
receptor in eyes with pseudoexfoliation syndrome and glaucoma.
Invest Ophthalmol Vis Sci. 46:2023–2034. 2005.
|
|
30
|
Zhang M, Budak MT, Lu W, et al:
Identification of the A3 adenosine receptor in rat
retinal ganglion cells. Mol Vis. 12:937–948. 2006.
|
|
31
|
Hu H, Lu W, Zhang M, et al: Stimulation of
the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye
Res. 91:425–432. 2010. View Article : Google Scholar
|
|
32
|
Bar-Yehuda S, Luger D, Ochaion A, et al:
Inhibition of experimental auto-immune uveitis by the A3
adenosine receptor agonist CF101. Int J Mol Med. 28:727–731.
2011.PubMed/NCBI
|
|
33
|
Avila MY, Stone RA and Civan MM: Knockout
of A3 adenosine receptors reduces mouse intraocular
pressure. Invest Ophthalmol Vis Sci. 43:3021–3026. 2002.PubMed/NCBI
|
|
34
|
Jacobson KA, von Lubitz DK, Daly JW and
Fredholm BB: Adenosine receptor ligands: differences with acute
versus chronic treatment. Trends Pharmacol Sci. 17:108–113. 1996.
View Article : Google Scholar : PubMed/NCBI
|
